Stockholm - Free Realtime Quote SEK
NextCell Pharma AB (NXTCL.ST)
1.1820
-0.0340
(-2.80%)
As of 2:46:15 PM GMT+2. Market Open.
Key Executives
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mathias Svahn Ph.D. | Founder & CEO | 983.53k | -- | 1976 |
| Mr. Patrik Fagerholm | Chief Financial Officer | -- | -- | 1967 |
| Mr. Lindsay Davies | Chief Scientific Officer | -- | -- | 1979 |
| Mr. Edvard Smith | Chief Medical Officer & Director | -- | -- | 1951 |
| Sofie Falk Jansson | CEO of Cellaviva | -- | -- | 1986 |
| Ms. Sofia Sisay | Head of Clinical Trials | -- | -- | 1981 |
NextCell Pharma AB
Karolinska Institutet Science Park
Hälsovägen 7
Huddinge, 141 57
Sweden
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 24
Description
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is based in Huddinge, Sweden.
Corporate Governance
NextCell Pharma AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available